What is the global market size of Peptide Therapeutics Market?

Global Peptide Therapeutics Market size was valued at USD 40.69 billion in 2021 and is poised to grow from USD 43.11 billion in 2022 to USD 68.4 billion by 2030, growing at a CAGR of 5.94% in the forecast period (2023-2030).

Who are the key vendors in the Global Peptide Therapeutics Market?

Technology innovations and the development of new products are important techniques used by companies to acquire market share. Additionally, it is predicted that growing alliances for conducting new drug trials will enhance rivalry in the industry. For instance, Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced a new agreement in May 2022, according to which Pfizer will procure Biohaven, the producer of NURTEC ODT, an advanced dual-acting migraine therapy approved for both acute treatments and episodic migraine prevention in adults. The key market players involved in the manufacture of automotive gears includes; 'Amgen, Inc.', 'AstraZeneca plc', 'Bachem Holding AG', 'Bristol-Myers Squibb Company', 'Eli Lilly and Company', 'Ipsen S.A.', 'Merck & Co., Inc.', 'Novartis AG', 'Novo Nordisk A/S', 'Pfizer Inc.', 'Sanofi S.A.', 'Takeda Pharmaceutical Company Limited', 'Teva Pharmaceutical Industries Ltd.', 'Lonza Group AG', 'Ferring Pharmaceuticals, Inc.', 'PolyPeptide Group', 'Protagonist Therapeutics, Inc.', 'Ipsen Biopharmaceuticals, Inc.', 'Polytherapeutics Inc.', 'Zealand Pharma A/S'

What is the key driver of Global Peptide Therapeutics Market?

Due to their high specificity, discernment, tiny sizes, simplicity of modification, and high biocompatibility, peptide therapies are used as targets in the administration of anti-cancer medications. The segment is expanding due to elements like the rising cancer burden, new launches, and research and development.

What is the key market trend for Global Peptide Therapeutics Market?

The majority of peptide medications are currently given through the parenteral route, and about 75% are given as injectables. However, in accordance with the corresponding technological advancements, alternate administration modalities, including as oral, intranasal, and transdermal delivery routes, are gaining more and more popularity.

Which region accounted for the largest share in Global Peptide Therapeutics Market?

The peptide therapeutics market was dominated by North America in 2021. The rise of the regional market is primarily attributed to the expansion of the biotechnology industry, increasing demand for cancer and other disease diagnostics, and expanding consumer awareness of peptide treatment products. Additionally, it is projected that increased government spending on R&D will support peptide treatments' continued supremacy over the forecast period. The region's well-established biotech and pharmaceutical sectors are a major contributor to the expansion. According to the American Cancer Society, 1.9 million more cancer cases are expected in the United States in 2022. Cancer is the second most common cause of death in the country, behind heart disease.

Peptide Therapeutics Market Size, Share, Growth Analysis, By Application(Cancer, Metabolic, Cardiovascular Disorder, Respiratory), By Type of Manufacturers(In-house, Outsourced), By Type(Generic, Innovative), By Route of Administration(Parenteral, Oral, Pulmonary, Mucosal), By Synthesis Technology(Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2072 | Region: Global | Published Date: February, 2024
Pages: 213 | Tables: 152 | Figures: 78

Peptide Therapeutics Market News

In August 2024, cGMP peptide manufacturing capacity was completed at a pharmaceutical manufacturing facility in Yangzhou, China. The move was triggered by the investment from Aurisco Pharmaceutical to expand the production of Aurisco’s generic GLP-1 peptides.
In February 2024, a new company entered the peptide therapeutics market with around USD 28 million in funding. Orbis Medicines was launched with the intention of developing macrocyclic peptides for a wide variety of disease indications. Novo Holdings and Forbion led the financial seed raise round for Orbis.
Back in December 2023, SynCrest Inc. In collaboration with Otsuka Chemical Co., Ltd., and Yokogawa Electric Corp. announced the launch of its CDRMO services for peptide therapeutics. Through this announcement, the company made its services accessible to pharmaceutical organizations working in South America, Japan, North America, and Europe.

Peptide Therapeutics Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Peptide Therapeutics Market size was valued at USD 40.69 billion in 2019 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).

Peptide therapeutics providers around the world are estimated to focus on research to maximize their business potential and stay competitive. Developing new therapeutics for different diseases indications will also be a preferred strategy for new as well as leading peptide therapeutics companies. Taking advantage of supportive government initatives to promote medical R&D will also create new opportunities in the future. 'Amgen, Inc.', 'AstraZeneca plc', 'Bachem Holding AG', 'Bristol-Myers Squibb Company', 'Eli Lilly and Company', 'Ipsen S.A.', 'Merck & Co., Inc.', 'Novartis AG', 'Novo Nordisk A/S', 'Pfizer Inc.', 'Sanofi S.A.', 'Takeda Pharmaceutical Company Limited', 'Teva Pharmaceutical Industries Ltd.', 'Lonza Group AG', 'Ferring Pharmaceuticals, Inc.', 'PolyPeptide Group', 'Protagonist Therapeutics, Inc.', 'Ipsen Biopharmaceuticals, Inc.', 'Polytherapeutics Inc.', 'Zealand Pharma A/S'

Poor lifestyle choices and growing adoption of unhealthy habits have lead to a major surge in incidence of chronic diseases around the world. As prevalence of diabetes, cancer, and other diseases rises, so does the need for better treatment for the same also rises. Low toxicity of peptide therapeutics makes them a preferred choice for treatment for multiple chronic diseases.

Development of Oral Peptide therapeutics: Peptide therapeutics companies can focus on the development of oral peptide therapeutics which are currently not widely available in the market. Heavy investments in research would be required to develop peptide therapeutics that can be administered orally but will pay of big time for any company who dives into this trend going forward.

North America is estimated to secure the top spot when it comes to the peptide therapeutics market. Increasing incidence of chronic diseases and high investments in medical research are forecasted to be the key factors contributing to the dominance of this region. Presence of key pharmaceutical manufacturers, rising awareness regarding benefits of peptide therapeutics, and supportive government funding to boost medical R&D are also expected to bolster sales of peptide therapeutics in this region. The United States is projected to lead the demand for peptide therapeutics in North America followed by Canada.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Peptide Therapeutics Market News

Peptide Therapeutics Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Peptide Therapeutics Market?

Who are the key vendors in the Peptide Therapeutics Market?

What is the key driver of Peptide Therapeutics Market?

What is the key market trend for Peptide Therapeutics Market?

Which region accounted for the largest share in Peptide Therapeutics Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300